Dengue Vaccine - Global Market Trajectory & Analytics

Global Dengue Vaccine Market to Reach $962.1 Million by 2027

Amid the COVID-19 crisis, the global market for Dengue Vaccine estimated at US$340 Million in the year 2020, is projected to reach a revised size of US$962.1 Million by 2027, growing at a CAGR of 16% over the analysis period 2020-2027. Government Institutions, one of the segments analyzed in the report, is projected to record a 15.2% CAGR and reach US$490.4 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Hospitals segment is readjusted to a revised 16.6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $97.8 Million, While China is Forecast to Grow at 20.9% CAGR

The Dengue Vaccine market in the U.S. is estimated at US$97.8 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$193.1 Million by the year 2027 trailing a CAGR of 20.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11.6% and 14.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 12.8% CAGR.

NGOs Segment to Record 17.6% CAGR

In the global NGOs segment, USA, Canada, Japan, China and Europe will drive the 16.6% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$38.8 Million in the year 2020 will reach a projected size of US$113.5 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$152.3 Million by the year 2027, while Latin America will expand at a 19.4% CAGR through the analysis period.

Select Competitors (Total 44 Featured):

Biological E. Ltd.
GlaxoSmithKline plc
Instituto Butantan
Panacea Biotec Ltd.
Sanofi SA
Takeda Pharmaceuticals Company Ltd.
Vabiotech

Frequently Asked Questions about the Global Market for Dengue Vaccine

What is the estimated value of the Global Market for Dengue Vaccine?

The Global Market for Dengue Vaccine was estimated to be valued at $340 Million in 2020.

What is the growth rate of the Global Market for Dengue Vaccine?

The growth rate of the Global Market for Dengue Vaccine is 16.0%, with an estimated value of $962.1 Million by 2027.

What is the forecasted size of the Global Market for Dengue Vaccine?

The Global Market for Dengue Vaccine is estimated to be worth $962.1 Million by 2027.

Who are the key companies in the Global Market for Dengue Vaccine?

Key companies in the Global Market for Dengue Vaccine include Biological E. Ltd., GlaxoSmithKline plc, Instituto Butantan, Panacea Biotec Ltd., Sanofi SA and Vabiotech.

Report Attribute	Details
Published	April 2021
Forecast Period	2020 - 2027
Estimated Market Value ( USD ) in 2020	$ 340 Million
Forecasted Market Value ( USD ) by 2027	$ 962.1 Million
Compound Annual Growth Rate	16.0%
Regions Covered	Global

I. METHODOLOGYII. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

Table 1: World Current & Future Analysis for Dengue Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
Table 2: World Historic Review for Dengue Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 3: World 15-Year Perspective for Dengue Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2018 & 2027
Table 4: World Current & Future Analysis for Government Institutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
Table 5: World Historic Review for Government Institutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 6: World 15-Year Perspective for Government Institutions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027
Table 7: World Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
Table 8: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 9: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027
Table 10: World Current & Future Analysis for NGOs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
Table 11: World Historic Review for NGOs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 12: World 15-Year Perspective for NGOs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 13: USA Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
Table 14: USA Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 15: USA 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
CANADA
Table 16: Canada Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
Table 17: Canada Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 18: Canada 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
JAPAN
Table 19: Japan Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
Table 20: Japan Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 21: Japan 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
CHINA
Table 22: China Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
Table 23: China Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 24: China 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
EUROPE
Table 25: Europe Current & Future Analysis for Dengue Vaccine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
Table 26: Europe Historic Review for Dengue Vaccine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 27: Europe 15-Year Perspective for Dengue Vaccine by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2018 & 2027
Table 28: Europe Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
Table 29: Europe Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 30: Europe 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
FRANCE
Table 31: France Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
Table 32: France Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 33: France 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
GERMANY
Table 34: Germany Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
Table 35: Germany Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 36: Germany 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
ITALY
Table 37: Italy Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
Table 38: Italy Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 39: Italy 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
UNITED KINGDOM
Table 40: UK Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
Table 41: UK Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 42: UK 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
SPAIN
Table 43: Spain Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
Table 44: Spain Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 45: Spain 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
RUSSIA
Table 46: Russia Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
Table 47: Russia Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 48: Russia 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
REST OF EUROPE
Table 49: Rest of Europe Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
Table 50: Rest of Europe Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 51: Rest of Europe 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
ASIA-PACIFIC
Table 52: Asia-Pacific Current & Future Analysis for Dengue Vaccine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
Table 53: Asia-Pacific Historic Review for Dengue Vaccine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 54: Asia-Pacific 15-Year Perspective for Dengue Vaccine by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2018 & 2027
Table 55: Asia-Pacific Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
Table 56: Asia-Pacific Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 57: Asia-Pacific 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
AUSTRALIA
Table 58: Australia Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
Table 59: Australia Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 60: Australia 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
INDIA
Table 61: India Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
Table 62: India Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 63: India 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
SOUTH KOREA
Table 64: South Korea Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
Table 65: South Korea Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 66: South Korea 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
REST OF ASIA-PACIFIC
Table 67: Rest of Asia-Pacific Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
Table 68: Rest of Asia-Pacific Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 69: Rest of Asia-Pacific 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
LATIN AMERICA
Table 70: Latin America Current & Future Analysis for Dengue Vaccine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
Table 71: Latin America Historic Review for Dengue Vaccine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 72: Latin America 15-Year Perspective for Dengue Vaccine by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2018 & 2027
Table 73: Latin America Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
Table 74: Latin America Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 75: Latin America 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
ARGENTINA
Table 76: Argentina Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
Table 77: Argentina Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 78: Argentina 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
BRAZIL
Table 79: Brazil Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
Table 80: Brazil Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 81: Brazil 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
MEXICO
Table 82: Mexico Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
Table 83: Mexico Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 84: Mexico 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
REST OF LATIN AMERICA
Table 85: Rest of Latin America Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
Table 86: Rest of Latin America Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 87: Rest of Latin America 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
MIDDLE EAST
Table 88: Middle East Current & Future Analysis for Dengue Vaccine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
Table 89: Middle East Historic Review for Dengue Vaccine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 90: Middle East 15-Year Perspective for Dengue Vaccine by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2018 & 2027
Table 91: Middle East Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
Table 92: Middle East Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 93: Middle East 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
IRAN
Table 94: Iran Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
Table 95: Iran Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 96: Iran 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
ISRAEL
Table 97: Israel Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
Table 98: Israel Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 99: Israel 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
SAUDI ARABIA
Table 100: Saudi Arabia Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
Table 101: Saudi Arabia Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 102: Saudi Arabia 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
UNITED ARAB EMIRATES
Table 103: UAE Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
Table 104: UAE Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 105: UAE 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
REST OF MIDDLE EAST
Table 106: Rest of Middle East Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
Table 107: Rest of Middle East Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 108: Rest of Middle East 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027
AFRICA
Table 109: Africa Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
Table 110: Africa Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
Table 111: Africa 15-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2012, 2018 & 2027